达雷妥尤单抗-话题@MedSci

#达雷妥尤单抗#

1篇内容 | 1041人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2195283, encodeId=012c2195283e4, content=<a href='/topic/show?id=7f389396e27' target=_blank style='color:#2F92EE;'>#达雷妥尤单抗#</a> <a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a> <a href='/topic/show?id=4322112e3501' target=_blank style='color:#2F92EE;'>#多中心回顾性研究#</a>, objectTitle=Ann Hematol：埃罗妥珠单抗治疗多发性骨髓瘤疗效在达雷妥尤单抗治疗后恶化——多中心回顾性研究, objectType=article, longId=817860, objectId=e9c081e860c8, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221120/1669014377311_4754896.jpeg, objectUrl=/article/show_article.do?id=e9c081e860c8, replyNumber=0, likeNumber=15, createdTime=2024-03-25, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=e9c081e860c8, moduleTitle=Ann Hematol：埃罗妥珠单抗治疗多发性骨髓瘤疗效在达雷妥尤单抗治疗后恶化——多中心回顾性研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e9c081e860c8)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2194644, encodeId=e7242194644a3, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a> <a href='/topic/show?id=7f389396e27' target=_blank style='color:#2F92EE;'>#达雷妥尤单抗#</a> <a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=JCO | CASTOR研究：达雷妥尤单抗、硼替佐米和地塞米松在多发性骨髓瘤患者中的生存期改善, objectType=article, longId=817693, objectId=6bff81e69349, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240321/1711034390272_6145188.jpg, objectUrl=/article/show_article.do?id=6bff81e69349, replyNumber=0, likeNumber=16, createdTime=2024-03-22, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=6bff81e69349, moduleTitle=JCO | CASTOR研究：达雷妥尤单抗、硼替佐米和地塞米松在多发性骨髓瘤患者中的生存期改善, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6bff81e69349)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2194237, encodeId=7bde219423e20, content=<a href='/topic/show?id=7f389396e27' target=_blank style='color:#2F92EE;'>#达雷妥尤单抗#</a> <a href='/topic/show?id=9ce61124e3ba' target=_blank style='color:#2F92EE;'>#免疫调节剂方案#</a> <a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>, objectTitle=Blood Cancer J：达雷妥尤单抗+免疫调节剂方案在多发性骨髓瘤的二线治疗中显示出更好的无进展生存期, objectType=article, longId=817520, objectId=c5d981e52030, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240319/1710862961800_6145188.jpg, objectUrl=/article/show_article.do?id=c5d981e52030, replyNumber=0, likeNumber=14, createdTime=2024-03-20, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=c5d981e52030, moduleTitle=Blood Cancer J：达雷妥尤单抗+免疫调节剂方案在多发性骨髓瘤的二线治疗中显示出更好的无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c5d981e52030)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2191001, encodeId=9ac5219100168, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a> <a href='/topic/show?id=aa77602136' target=_blank style='color:#2F92EE;'>#DKD#</a> <a href='/topic/show?id=7f389396e27' target=_blank style='color:#2F92EE;'>#达雷妥尤单抗#</a> <a href='/topic/show?id=cd1811189937' target=_blank style='color:#2F92EE;'>#DPd#</a>, objectTitle=【EJH】DPd对比DKd治疗达雷妥尤单抗未暴露RRMM的回顾性研究, objectType=article, longId=815866, objectId=05908158664d, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/close-up-of-doctors-with-clipboard-at-hospital-PXE5DKE.jpg, objectUrl=/article/show_article.do?id=05908158664d, replyNumber=0, likeNumber=21, createdTime=2024-03-04, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=05908158664d, moduleTitle=【EJH】DPd对比DKd治疗达雷妥尤单抗未暴露RRMM的回顾性研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=05908158664d)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2190377, encodeId=68f521903e7ff, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a> <a href='/topic/show?id=a04e4135027' target=_blank style='color:#2F92EE;'>#地塞米松#</a> <a href='/topic/show?id=3ec02566625' target=_blank style='color:#2F92EE;'>#伊沙佐米#</a> <a href='/topic/show?id=7f389396e27' target=_blank style='color:#2F92EE;'>#达雷妥尤单抗#</a> <a href='/topic/show?id=12ab111e84e7' target=_blank style='color:#2F92EE;'>#来那度胺暴露#</a>, objectTitle=【AJH】达雷妥尤单抗+伊沙佐米+地塞米松治疗来那度胺暴露二线RRMM的2期DARIA研究结果, objectType=article, longId=815280, objectId=9d6981528062, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/busy-hospital-corridor-with-medical-staff-and-PHNLKBC.jpg, objectUrl=/article/show_article.do?id=9d6981528062, replyNumber=0, likeNumber=17, createdTime=2024-03-01, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=9d6981528062, moduleTitle=【AJH】达雷妥尤单抗+伊沙佐米+地塞米松治疗来那度胺暴露二线RRMM的2期DARIA研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9d6981528062)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2188739, encodeId=fb612188e39c8, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a> <a href='/topic/show?id=a4671201218' target=_blank style='color:#2F92EE;'>#MM#</a> <a href='/topic/show?id=a04e4135027' target=_blank style='color:#2F92EE;'>#地塞米松#</a> <a href='/topic/show?id=7f389396e27' target=_blank style='color:#2F92EE;'>#达雷妥尤单抗#</a> <a href='/topic/show?id=1bf011141e3e' target=_blank style='color:#2F92EE;'>#塞利尼索#</a>, objectTitle=【Haematologica】塞利尼索+达雷妥尤单抗+Vd治疗RRMM的II期研究, objectType=article, longId=814080, objectId=882f81408000, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-writing-D3K6QME.jpg, objectUrl=/article/show_article.do?id=882f81408000, replyNumber=0, likeNumber=17, createdTime=2024-02-22, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=882f81408000, moduleTitle=【Haematologica】塞利尼索+达雷妥尤单抗+Vd治疗RRMM的II期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=882f81408000)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2177467, encodeId=b3f921e7467fc, content=<a href='/topic/show?id=a04e4135027' target=_blank style='color:#2F92EE;'>#地塞米松#</a> <a href='/topic/show?id=c34d64e47d1' target=_blank style='color:#2F92EE;'>#泊马度胺#</a> <a href='/topic/show?id=7f389396e27' target=_blank style='color:#2F92EE;'>#达雷妥尤单抗#</a> <a href='/topic/show?id=6ec61050e7b0' target=_blank style='color:#2F92EE;'>#RRMM#</a>, objectTitle=2023 ASH真实世界研究：泊马度胺、达雷妥尤单抗、地塞米松联合方案（DPd）较DKd延长RRMM患者OS, objectType=article, longId=806561, objectId=31fe806561d8, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-filling-form-U2MAYRK.jpg, objectUrl=/article/show_article.do?id=31fe806561d8, replyNumber=0, likeNumber=25, createdTime=2023-12-27, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=31fe806561d8, moduleTitle=2023 ASH真实世界研究：泊马度胺、达雷妥尤单抗、地塞米松联合方案（DPd）较DKd延长RRMM患者OS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=31fe806561d8)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2175858, encodeId=250221e5858dc, content=<a href='/topic/show?id=7f389396e27' target=_blank style='color:#2F92EE;'>#达雷妥尤单抗#</a> <a href='/topic/show?id=2e1610881935' target=_blank style='color:#2F92EE;'>#高危多发性骨髓瘤#</a>, objectTitle=Blood Adv：两项3期研究的事后分析，早期复发MM可获益于达雷妥尤单抗, objectType=article, longId=804166, objectId=e5d2804166d8, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/medical-conference-P42ZDP5.jpg, objectUrl=/article/show_article.do?id=e5d2804166d8, replyNumber=0, likeNumber=36, createdTime=2023-12-19, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=e5d2804166d8, moduleTitle=Blood Adv：两项3期研究的事后分析，早期复发MM可获益于达雷妥尤单抗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e5d2804166d8)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1222743, encodeId=b9181222e43e6, content=<a href='/topic/show?id=7f389396e27' target=_blank style='color:#2F92EE;'>#达雷妥尤单抗#</a>+<a href='/topic/show?id=518761566e4' target=_blank style='color:#2F92EE;'>#来那度胺#</a>一线治疗不适移植的<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>的疗效可期！, objectTitle=Lancet oncol：3期| 达雷妥尤单抗+来那度胺一线治疗不适移植的多发性骨髓瘤的疗效可期！, objectType=article, longId=218592, objectId=454b218592dd, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20211015/1634282603340_2570354.jpg, objectUrl=/article/show_article.do?id=454b218592dd, replyNumber=0, likeNumber=96, createdTime=2022-05-27, rootId=0, userName=清风徐来2022, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=454b218592dd, moduleTitle=Lancet oncol：3期| 达雷妥尤单抗+来那度胺一线治疗不适移植的多发性骨髓瘤的疗效可期！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=454b218592dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

达雷妥尤单抗

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#达雷妥尤单抗# #多发性骨髓瘤# #多中心回顾性研究#

Ann Hematol：埃罗妥珠单抗治疗多发性骨髓瘤疗效在达雷妥尤单抗治疗后恶化——多中心回顾性研究

2024-03-25发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#多发性骨髓瘤# #达雷妥尤单抗# #总生存期#

JCO | CASTOR研究：达雷妥尤单抗、硼替佐米和地塞米松在多发性骨髓瘤患者中的生存期改善

2024-03-22发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#达雷妥尤单抗# #免疫调节剂方案# #多发性骨髓瘤#

Blood Cancer J：达雷妥尤单抗+免疫调节剂方案在多发性骨髓瘤的二线治疗中显示出更好的无进展生存期

2024-03-20发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#多发性骨髓瘤# #DKD# #达雷妥尤单抗# #DPd#

【EJH】DPd对比DKd治疗达雷妥尤单抗未暴露RRMM的回顾性研究

2024-03-04发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#多发性骨髓瘤# #地塞米松# #伊沙佐米# #达雷妥尤单抗# #来那度胺暴露#

【AJH】达雷妥尤单抗+伊沙佐米+地塞米松治疗来那度胺暴露二线RRMM的2期DARIA研究结果

2024-03-01发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#多发性骨髓瘤# #MM# #地塞米松# #达雷妥尤单抗# #塞利尼索#

【Haematologica】塞利尼索+达雷妥尤单抗+Vd治疗RRMM的II期研究

2024-02-22发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#地塞米松# #泊马度胺# #达雷妥尤单抗# #RRMM#

2023 ASH真实世界研究：泊马度胺、达雷妥尤单抗、地塞米松联合方案（DPd）较DKd延长RRMM患者OS

2023-12-27发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#达雷妥尤单抗# #高危多发性骨髓瘤#

Blood Adv：两项3期研究的事后分析，早期复发MM可获益于达雷妥尤单抗

2023-12-19发表于上海

清风徐来2022 (审核中...)

前往app查看评论内容

#达雷妥尤单抗#+#来那度胺#一线治疗不适移植的#多发性骨髓瘤#的疗效可期！

Lancet oncol：3期| 达雷妥尤单抗+来那度胺一线治疗不适移植的多发性骨髓瘤的疗效可期！

2022-05-27

科室
- - 订阅+
  - 更多科室
工具
服务